title: [Blood tumor markers in patients with lung cancer].
abstract: Over the past years, a number of serum components have been confirmed as useful biological markers of lung cancer. Although none have been sensitive or specific enough to enable early diagnosis, they do seem to facilitate the monitoring and prediction of disease prognosis. We studied tumor markers in 66 patients with lung cancer: serum levels of ferritin, carcinoembryonic antigen (CEA), alpha-fetoprotein (alpha-FP); tissue polypeptide antigen (TPA), cytocheratin fragment 19, 21-1 (CYFRA 21-1) and carbohydrate antigen 125 (CA 125) levels were measured and correlated to tumor stage and histological type. Postulating a specificity of 95% versus benign diseases of the lung, we confirmed the following diagnostic sensitivity for the markers: ferritin = 39.3%; CEA = 42.4%; alpha-FP = 5.1%; TPA = 57.5%; CYFRA 21-1 = 65.1%; CA 125 = 46.9%. CYFRA 21-1 showed significantly higher sensitivity in non small cell lung cancer patients than in those with small cell lung cancer (Wilcoxon, p = 0.02). Moreover since survival time was significantly shorter in patients with high serum CYFRA 21-1, these levels seemed to be correlated with the prognosis.
authors.affiliation: Istituto di Tisiologia e Malattie dell'Apparato Respiratorio S. Marcatili, Facoltà di Medicina e Chirurgia, Seconda Università degli Studi di Napoli.
authors.forename: A
authors.initials: A
authors.lastname: Bianco
authors.forename: P
authors.initials: P
authors.lastname: Marcatili
authors.forename: D
authors.initials: D
authors.lastname: D'Auria
authors.forename: P
authors.initials: P
authors.lastname: Sorrentino
authors.forename: S
authors.initials: S
authors.lastname: Zofra
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor
vernacular_title: Marcatori tumorali sierici in pazienti con cancro del polmone.